Literature DB >> 28671717

The effect of interleukin (IL)-21 and CD4+ CD25++ T cells on cytokine production of CD4+ responder T cells in patients with myasthenia gravis.

M Alahgholi-Hajibehzad1,2, H Durmuş3, F Aysal4, Y Gülşen-Parman3, P Oflazer3, F Deymeer3, G Saruhan-Direskeneli1.   

Abstract

Impairment of the suppressive function of regulatory T (Treg ) cells has been reported in myasthenia gravis (MG). In this study, cytokine-related mechanisms that may lead to the defect of Treg were investigated in patients with anti-acetylcholine receptor antibody-positive MG (AChR + MG). Proliferation and cytokine production of responder T (Tresp ) cells in response to polyclonal activation were measured in a suppression assay. The effect of interleukin (IL)-21 on suppression was evaluated in vitro in co-culture. IL-21 increased the proliferation of Tresp cells in Tresp /Treg co-cultures. Tresp cells from patients with MG secreted significantly lower levels of IL-2. In patients with MG, IL-2 levels did not change with the addition of Treg to cultures, whereas it decreased significantly in controls. In Tresp /Treg co-cultures, IL-4, IL-6 and IL-10 production increased in the presence of Treg in patients. Interferon (IFN)-γ was decreased, whereas IL-17A was increased in both patient and control groups. IL-21 inhibited the secretion of IL-4 in MG and healthy controls (HC), and IL-17A in HC only. The results demonstrated that IL-21 enhances the proliferation of Tresp cells in the presence of Treg . An effect of IL-21 mainly on Tresp cells through IL-2 is implicated.
© 2017 British Society for Immunology.

Entities:  

Keywords:  IL-21; Treg; cytokine; myasthenia gravis

Mesh:

Substances:

Year:  2017        PMID: 28671717      PMCID: PMC5629443          DOI: 10.1111/cei.13006

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  32 in total

1.  IL-21 counteracts the regulatory T cell-mediated suppression of human CD4+ T lymphocytes.

Authors:  Ilaria Peluso; Massimo Claudio Fantini; Daniele Fina; Roberta Caruso; Monica Boirivant; Thomas T MacDonald; Francesco Pallone; Giovanni Monteleone
Journal:  J Immunol       Date:  2007-01-15       Impact factor: 5.422

2.  Increased interleukin 21 and follicular helper T-like cells and reduced interleukin 10+ B cells in patients with new-onset systemic lupus erythematosus.

Authors:  Li Wang; Pingwei Zhao; Liang Ma; Yuxing Shan; Zhenyu Jiang; Juan Wang; Yanfang Jiang
Journal:  J Rheumatol       Date:  2014-07-15       Impact factor: 4.666

3.  Both Treg cells and Tconv cells are defective in the Myasthenia gravis thymus: roles of IL-17 and TNF-α.

Authors:  Angeline Gradolatto; Dani Nazzal; Frédérique Truffault; Jacky Bismuth; Elie Fadel; Maria Foti; Sonia Berrih-Aknin
Journal:  J Autoimmun       Date:  2014-01-07       Impact factor: 7.094

Review 4.  The role of T regulatory cells in immunopathogenesis of myasthenia gravis: implications for therapeutics.

Authors:  Mahdi Alahgholi-Hajibehzad; Pinar Kasapoglu; Reza Jafari; Nima Rezaei
Journal:  Expert Rev Clin Immunol       Date:  2015-05-14       Impact factor: 4.473

Review 5.  Advances in IL-21 biology - enhancing our understanding of human disease.

Authors:  Stuart G Tangye
Journal:  Curr Opin Immunol       Date:  2015-03-23       Impact factor: 7.486

6.  Foxp3 programs the development and function of CD4+CD25+ regulatory T cells.

Authors:  Jason D Fontenot; Marc A Gavin; Alexander Y Rudensky
Journal:  Nat Immunol       Date:  2003-03-03       Impact factor: 25.606

Review 7.  Beyond regulatory T cells: the potential role for IL-2 to deplete T-follicular helper cells and treat autoimmune diseases.

Authors:  André Ballesteros-Tato
Journal:  Immunotherapy       Date:  2014       Impact factor: 4.196

8.  Acetylcholine receptor-reactive T cells in myasthenia gravis: evidence for the involvement of different subpopulations of T helper cells.

Authors:  Q Yi; R Ahlberg; R Pirskanen; A K Lefvert
Journal:  J Neuroimmunol       Date:  1994-03       Impact factor: 3.478

9.  Clinical efficacy and cytokine network-modulating effects of tacrolimus in myasthenia gravis.

Authors:  Yutaka Furukawa; Hiroaki Yoshikawa; Kazuo Iwasa; Masahito Yamada
Journal:  J Neuroimmunol       Date:  2008-02-11       Impact factor: 3.478

10.  Follicular helper T cell signature in type 1 diabetes.

Authors:  Rupert Kenefeck; Chun Jing Wang; Tauseef Kapadi; Lukasz Wardzinski; Kesley Attridge; Louise E Clough; Frank Heuts; Alexandros Kogimtzis; Sapna Patel; Miranda Rosenthal; Masahiro Ono; David M Sansom; Parth Narendran; Lucy S K Walker
Journal:  J Clin Invest       Date:  2014-12-08       Impact factor: 14.808

View more
  3 in total

1.  The increased T helper cells proliferation and inflammatory responses in patients with type 2 diabetes mellitus is suppressed by sitagliptin and vitamin D3 in vitro.

Authors:  Elham Mahabadi-Ashtiyani; Vida Sheikh; Shiva Borzouei; Iraj Salehi; Mahdi Alahgholi-Hajibehzad
Journal:  Inflamm Res       Date:  2019-06-25       Impact factor: 4.575

2.  Chinese Herbal Medicine for Myasthenia Gravis: A Systematic Review and Meta-Analysis.

Authors:  Shuang Chen; Meng-Bei Xu; Xiao-Li Zhou; Pei-Qing Rong; Ting-Yu Jin; Guo-Qing Zheng
Journal:  Front Pharmacol       Date:  2018-08-30       Impact factor: 5.810

Review 3.  B cell-T cell interplay in immune regulation: A focus on follicular regulatory T and regulatory B cell functions.

Authors:  Diaoyi Tan; Wei Yin; Fei Guan; Wanjiang Zeng; Pamela Lee; Fabio Candotti; Louisa K James; Niels Olsen Saraiva Camara; S M Mansour Haeryfar; Yan Chen; Kamel Benlagha; Lewis Zhichang Shi; Jiahui Lei; Quan Gong; Zheng Liu; Chaohong Liu
Journal:  Front Cell Dev Biol       Date:  2022-09-23
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.